Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
figureposted on 2020-09-01, 16:07 authored by Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group
The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.